	US 12,077,562 B2
	AAV capsids identified by in vivo library selection
Miguel Sena Esteves, Westford, MA (US); Sourav Roy Choudhury, Newton, MA (US); Kathryn Rae Wagner, Baltimore, MD (US); Jennifer Gifford Green, Chelmsford, MA (US); and Ana Rita Batista, West Boylston, MA (US)
Assigned to University of Massachusetts, Boston, MA (US); The Johns Hopkins University, Baltimore, MD (US); and Kennedy Krieger Institute, Inc., Baltimore, MD (US)
Filed by University of Massachusetts, Boston, MA (US); The Johns Hopkins University, Baltimore, MD (US); and Kennedy Krieger Institute, Inc., Baltimore, MD (US)
Filed on Sep. 7, 2022, as Appl. No. 17/930,166.
Application 17/930,166 is a continuation of application No. 17/050,475, granted, now 11,472,848, previously published as PCT/US2019/029489, filed on Apr. 26, 2019.
Claims priority of provisional application 62/663,988, filed on Apr. 27, 2018.
Prior Publication US 2023/0067741 A1, Mar. 2, 2023
Int. Cl. C07K 14/01 (2006.01); C07K 14/005 (2006.01); C07K 14/015 (2006.01); C07K 14/47 (2006.01); C12N 7/00 (2006.01); A61K 38/00 (2006.01)

CPC C07K 14/01 (2013.01) [C12N 7/00 (2013.01); A61K 38/00 (2013.01); C12N 2310/141 (2013.01); C12N 2750/14122 (2013.01)]

11 Claims

1. A method for delivering a transgene to a subject, the method comprising administering to the subject an rAAV comprising an isolated AAV capsid protein comprising the amino acid sequence set forth in SEQ ID NOs: 6 or 7, wherein the transgene comprises skeletal muscle-specific promoter.